CAU
PACB icon

Caxton Associates (UK)’s Pacific Biosciences PACB Stock Holding History

Caxton Associates (UK)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$466K Sell
353,130
-288,594
-45% -$516K 0.01% 517
2025
Q4 		$1.2M Buy
+641,724
New +$1.23M 0.02% 318

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caxton Associates (UK)'s PACB Position: Q1 2026 in Review

Caxton Associates (UK) reduced its Pacific Biosciences (PACB) stake by 45% in Q1 2026, selling an estimated $516K and leaving 353,130 shares worth $466K. The position accounts for 0.01% of the portfolio, ranked #517.

Caxton Associates (UK) first reported a position in PACB in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.2M in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Caxton Associates (UK) held 353,130 shares of Pacific Biosciences worth $466K as of Q1 2026.
  • Caxton Associates (UK) sold 288,594 Pacific Biosciences shares in Q1 2026, an estimated $516K.
  • Pacific Biosciences made up 0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #517 holding.
  • Caxton Associates (UK) first reported a position in Pacific Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Caxton Associates (UK)'s Pacific Biosciences position peaked at $1.2M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.